DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Negative impactSector

Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Dispute

NDTV Profit 13 Jul·13 Jul 2026, 11:20 am

Delhi High Court temporarily halted supplies of Zydus Lifesciences' cancer drug Ikra.

Affected stocks

Bearish1 stock

Zydus Lifesciences

ZYDUSLIFE Bearish

₹1,150.80

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Zydus Lifesciences (ZYDUSLIFE).
Category: Sector.
AI reads the tone as negative (potentially bearish) for the stock.

Why it matters

A routine update for Zydus Lifesciences. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NDTV Profit.